Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
The invention provides a T cell wherein one or more therapeutic transgenes is integrated at a within the genome of the cell such that expression of the transgene is under control of an endogenous promoter of the T cell. The invention additional provides methods of making and using such cells to treat a subject with T cell therapy. The invention also provides a T cell wherein a recombinant nucleic acid sequence encoding a chimeric antigen receptor (CAR) is integrated at a first site within the genome of the cell such that the CAR is expressed by the cell at the surface of the cell, and wherein integration of the nucleic acid encoding the CAR at the first site reduces or prevents expression of a functional T cell receptor (TCR) complex at the surface of the cell. The invention additional provides methods of making and using such cells to treat a subject with CAR therapy.
1. A human T cell wherein a promoter-less recombinant nucleic acid sequence encoding a CAR is integrated at a site in the genome of the cell, said site being the first exon of the T cell receptor (TCR) alpha chain, such that the CAR is expressed under control of the endogenous TCR alpha chain promoter, to produce said CAR at the surface of the cell, and wherein integration of the nucleic acid sequence encoding the CAR at said site prevents expression of a functional TCR alpha chain.
2. The human T cell of claim 1 , wherein the CAR binds to a cancer antigen.
3. The human T cell of claim 1 , wherein the nucleic acid sequence encoding the CAR is integrated into the first site by targeted homologous recombination.
4. The human T cell of claim 1 , wherein the CAR binds to CD19.
5. An isolated population of T cells, which comprises a plurality of the human T cell of claim 1 .
6. A pharmaceutical composition comprising a therapeutically effective amount of the human T cell of claim 1 ; and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising a therapeutically effective amount of a population of T cells, which population comprises a plurality of the human T cell of claim 1 ; and a pharmaceutically acceptable carrier.